News from Novo Nordisk A wide array of domestic and global news stories on topics including politics, business, technology, religion, sports, entertainment, science, health and lifestyle.

Latest News from Novo Nordisk

01 Feb, 2018, 08:30 GMT Semaglutide Demonstrated Significant Reductions in Blood Sugar and Weight Compared with Dulaglutide; Results Published in The Lancet Diabetes & Endocrinology

Results from the SUSTAIN 7 trial, which investigated the efficacy and safety of 0.5 mg semaglutide compared with 0.75 mg dulaglutide and 1.0 mg...


11 Dec, 2017, 08:00 GMT Xultophy® Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for People With Type 2 Diabetes in Real-World Setting

- Results published in Diabetes, Obesity and Metabolism Newly published data from real-world European clinical practice has...


07 Dec, 2017, 08:45 GMT Tresiba® Reduces Hypoglycaemia Regardless of Blood Sugar Level

People with either type 1 or type 2 diabetes treated with Tresiba® had fewer episodes of low blood sugar (hypoglycaemia) compared with people on...


07 Dec, 2017, 08:45 GMT Ryzodeg® Significantly Reduces the Risk of Low Blood Sugar in People With Type 2 Diabetes who Fast During Ramadan

In people with type 2 diabetes who fast during Ramadan, Ryzodeg® (insulin degludec/insulin aspart) reduced the overall rate of low blood sugar...


06 Dec, 2017, 08:01 GMT Interim Results of First-Ever Global Survey Show People with Type 2 Diabetes Underestimate their Cardiovascular Risk

- Globally, cardiovascular disease (CVD) is the most common cause of death in people with type 2 diabetes[1] - 1 in 3 respondents...


05 Dec, 2017, 09:00 GMT Switching to Tresiba® Benefits People with Diabetes Irrespective of Blood Sugar Levels in a Real-world Setting

- Switching to Tresiba® reduced the rate of hypoglycaemia by 67% in people with controlled blood sugar levels - In people with...


05 Dec, 2017, 06:00 GMT Xultophy® Reported a Better Option than Basal-Bolus Insulin Therapy to Manage Type 2 Diabetes by Participants in the DUAL VII Clinical Trial

Once-daily Xultophy® (insulin degludec/liraglutide) was a better option to manage diabetes compared to multiple daily injections of insulin...


06 Nov, 2017, 08:45 GMT Switching to Tresiba® is Highly Cost-effective and Cost-saving in a Real-world Setting

Poster Presentation PDB27 A new analysis of real-world data has shown that switching to Tresiba® (insulin degludec) is highly cost-effective and...


31 Oct, 2017, 12:00 GMT New US Study Reveals Key Reasons why Millions of People with Obesity are not Receiving Adequate Care

Despite increasing recognition of obesity as a disease, many barriers to effective care remain Few of the more than 90 million Americans with...


29 Sep, 2017, 07:00 BST IDF and Novo Nordisk Launch First-ever Global Survey on Cardiovascular Disease Awareness among People with Type 2 Diabetes

- Taking Diabetes to Heart is a global online survey for people with type 2 diabetes to gain important insights about their awareness of...


15 Sep, 2017, 08:31 BST Tresiba® Trial Shows that People with Type 2 Diabetes who Avoid Severe Hypoglycaemia have a Reduced Risk of Death

Symposium: S33 Novo Nordisk today announced new analyses from the multinational, double-blinded DEVOTE trial showing that people with type 2...


13 Sep, 2017, 15:31 BST Xultophy® Reduces Cardiovascular Risk Factors in People with Type 2 Diabetes

Oral Presentation 113 In people with type 2 diabetes, Xultophy® (insulin degludec/liraglutide) significantly reduced a number of risk factors...


12 Sep, 2017, 11:59 BST More People Treated With Once-weekly Semaglutide Achieved Reductions in Both Glucose and Weight vs. Comparator Treatments

Poster # 820 A post-hoc analysis of the SUSTAIN 1-5 trials demonstrated that a greater proportion of adults with type 2 diabetes achieved a...


12 Sep, 2017, 11:59 BST Fiasp® Significantly Improved Overall Blood Sugar Control in Type 1 Diabetes Long-term

Fiasp® (fast-acting insulin aspart), the only approved, new-generation, ultra-fast acting[1]-[3] mealtime insulin, improved overall blood sugar...


28 Aug, 2017, 13:00 BST Victoza® Reduces the Risk of Major Cardiovascular Events in People with Type 2 Diabetes With or Without Prior Events

Oral Presentation 3909 A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular...


03 Jul, 2017, 08:00 BST Novo Nordisk to Present 35 Abstracts at the International Society on Thrombosis and Haemostasis Congress

Novo Nordisk announced today that data from 35 abstracts will be presented at the upcoming International Society on Thrombosis and Haemostasis...


13 Jun, 2017, 02:30 BST New LEADER Analysis Shows Victoza® Reduces Cardiovascular Risk in People With Type 2 Diabetes Regardless of Severe Hypoglycaemia Events

Findings from a post hoc analysis of the LEADER cardiovascular (CV) outcomes trial showed that treatment with Victoza® (liraglutide) resulted in...


12 Jun, 2017, 22:15 BST Tresiba® Demonstrated No Increased Risk Of Major Cardiovascular Events and Significant Reduction in Rates of Severe Hypoglycaemia Compared to Insulin Glargine U100 in the DEVOTE Trial

Symposium: 3-CT-SY22 Novo Nordisk today announced the primary results from DEVOTE - the first randomised, double-blind, treat-to-target,...


10 Jun, 2017, 18:00 BST Switching to Tresiba® Provides Significant Reductions in Blood Glucose and Lower Rates of Hypoglycaemia in a Real-world Setting

Poster Presentations #999-P, #1010-P, #1014-P Findings from the real-world study, EU-TREAT (EUropean TREsiba AudiT), were presented today at the...


17 May, 2017, 15:30 BST Early Response to Saxenda® Resulted in Weight Maintenance and Additional Weight Loss Over 56 Weeks

Abstract# RS3:3 Today, results from a post hoc analysis of data from the SCALE Maintenance trial were presented at the 24th European Congress on...


02 Apr, 2017, 18:00 BST Once-weekly Semaglutide Demonstrated Consistent Blood Glucose Reductions and Weight Loss Regardless of Background Oral Antidiabetic Treatment

Abstract #620 Findings from a post hoc analysis of the phase 3a SUSTAIN 2-4 trials demonstrated greater mean reductions in HbA1c and body weight...


27 Mar, 2017, 08:00 BST Fiasp®▼, a new, ultra-fast acting mealtime insulin is available for the treatment of diabetes in adults

Canada first country to launch Fiasp® This material is intended for global medical media only. For journalistic assessment and preparation...


01 Feb, 2017, 07:00 GMT Flexible Storage Options can Impact Daily Use of FVIII Treatments in People with Haemophilia A

This material is intended for global medical media only. For journalistic assessment and preparation before publication. Poster #P024 Patient...


03 Dec, 2016, 17:00 GMT NovoSeven® Resolved 96.5% of Bleeds When Initiated Within One Hour After Bleed Onset in People With Haemophilia A or B With Inhibitors

This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today...


02 Dec, 2016, 08:00 GMT Xultophy®▼ (IDegLira) Demonstrates Similar Glucose Control With Reduced Risk of Hypoglycaemia and a Superior Weight Profile Compared to Basal-Bolus Therapy

This material is intended for UK medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today...